Special Winter 2024Protein Engineering and ServicesMonoclonal antibodies still dominate the US$417bn biologics market. After decades of development, however, improved antibodies and protein formats with better target selectivity and safety profiles … more ➔
Special Autumn 2024CDMOs & CROsA draft US Biosecure Act being passed by the US House of Representatives and discussed by the US Senate could prohibit US biotech developers from collaborating with Chinese CROs, CDMOs and drug developers … more ➔
Special Summer 2024Euro BioFairs CompassGuide to Life Sciences Events in the second half year of 2024 more ➔
Special Spring 2024Bioprocessing & Precision Fermentatio...The biotech and pharma branch is growing steadily. Many companies have full order books for the next few years and expect growth. This is the basis for new investments in assets and infrastructure. These … more ➔
Special Winter 2023Euro BioFairs CompassGuide to Life Sciences Events in the first half year of 2024 more ➔
Special Autumn 2023CROs & CDMOsSince 2006, the share of biomanufacturers producing everything in-house have declined from 57.6% to 34.9% in 2022. According to biopharmaceutical companies, the percentage is to decrease to 20% by 2026, … more ➔
